Ernexa Therapeutics Inc. Warrants (ERNAW) is a Asset management company in the Financial services sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Ernexa Therapeutics Inc. Warrants in 2026. The next earnings report is expected on November 11, 2026.
Next earnings date
11 Nov 2026
In 81 days
EPS estimate
-3.84
Revenue estimate
—
Past earnings
Latest earnings analysis
Ernexa Therapeutics Inc. Warrants missed consensus estimates in its latest earnings report, with EPS of $-6.95 versus an expected $-1.95, and revenue was not disclosed. No prior report is available for comparison.
No dividend history available.
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Ernexa Therapeutics Inc. Warrants (ERNAW) is scheduled to report earnings on November 11, 2026.
Ernexa Therapeutics Inc. Warrants (ERNAW) last reported earnings on August 6, 2026.
Ernexa Therapeutics Inc. Warrants (ERNAW) is listed on Nasdaq.
We use cookies to make our website work and improve your experience. With your consent, we also use cookies for analytics and advertising.